Substance Abuse/Drug Development: Medication Development

Deadline
Multiple
OPPORTUNITY NO.
PAR-16-431
MECHANISM
U01
RESEARCH AREA(S)
SYNOPSIS

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance-Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.  

Deadlines:

  • Pre-Application Submission: 30 days before application submission due date
  • Application Submission: 5:00 PM local time of applicant organization, Mar. 27, 2017; Jul. 25, 2017; Mar. 27, 2018; Jul. 25, 2018; Mar. 27, 2019; Jul. 25, 2019

ELIGIBILITY

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.